# Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Canonical URL: https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-b29aaf82
Ticker: HEPA
Company: Hepion Pharmaceuticals
Source: Hepion Pharmaceuticals
Published: 2025-05-12 20:30 EST
## Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public shell. The Notice indicated that trading in the Company’s shares of common stock (the “Common Stock”) on Nasdaq will be suspended effective at the open of trading on Tuesday, May 13, 2025.

## Article Body
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 per share and Nasdaq Listing Rule 5101 indicating that Nasdaq believes the Company is a public shell. The Notice indicated that trading in the Company’s shares of common stock (the “Common Stock”) on Nasdaq will be suspended effective at the open of trading on Tuesday, May 13, 2025.
## Recent Company News
- 2026-03-03 12:35 EST — [Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-in-licenses-ctrna-biomarker-assay-to-facilitate-early-dia-5419c60d) — Source: Hepion Pharmaceuticals
- 2025-06-25 12:30 EST — [Hepion Pharmaceuticals Successfully Completes Application to the OTCQB](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-successfully-completes-application-to-the-otcqb-9ba83e8c) — Source: Hepion Pharmaceuticals
- 2025-06-16 12:30 EST — [Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-dr-kaouthar-lbiati-as-interim-chief-executive-o-a94f00a0) — Source: Hepion Pharmaceuticals
- 2025-05-12 20:30 EST — [Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-announces-receipt-of-delisting-notification-from-nasdaq-b29aaf82) — Source: Hepion Pharmaceuticals
- 2025-05-07 12:30 EST — [Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC](https://biopharmsignal.com/news/HEPA/hepion-pharmaceuticals-executes-binding-letter-of-intent-with-new-day-diagnostic-4fed3351) — Source: Hepion Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)